Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02655692 · ClinicalTrials.gov registry record · Phase 2
CAP-Ketamine for Antidepressant Resistant PTSD
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT02655692: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT02655692 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 163 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02655692, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.
Interventions
- DRUG Ketamine
- DRUG Placebo/Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2016-04-18 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02655692
The ClinicalTrials.gov registry entry for NCT02655692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT02655692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02655692 about?
NCT02655692 is a clinical study titled "CAP-Ketamine for Antidepressant Resistant PTSD". The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.
What is the current status of trial NCT02655692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2016-04-18. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT02655692?
The interventions under investigation include: Ketamine (DRUG), Placebo/Saline (DRUG).
Who is sponsoring clinical trial NCT02655692?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.